 Home > Active Pharmaceutical Ingredients > Other Chemical Drugs > Pembrolizumab for Sale > Lambrolizumab 99% white powder cas1374853-91-4 senwayer

Lambrolizumab 99% white powder cas1374853-91-4 senwayer buy - large image1

Lambrolizumab 99% white powder cas1374853-91-4 senwayer buy - image1

Lambrolizumab 99% white powder cas1374853-91-4 senwayer buy - image2

Lambrolizumab 99% white powder cas1374853-91-4 senwayer buy - image3

Lambrolizumab 99% white powder cas1374853-91-4 senwayer

Name: Lambrolizumab 99% white powder cas1374853-91-4 senwayer
Brand: senwayer
SKU: pr2302151485
Price: 10 USD
Availability: InStock

3 Inquiries

Unit Price: Get Latest Price 

CAS No.:

1374853-91-4

Grade:

Pharmaceutical Grade

Content:

99%

Port:

guangzhou

Brand:

senwayer

Packaging:

1kg/bag

Price valid (until):

2022-07-31

Contact Supplier

 Chat Now

Dingwang Technology (Wuhan) Co., Ltd.

Company Type:

Trader

Location:

China

Payment Terms:

TT against copy of documents,L/C

Average Lead Time:

10 days

Qualification:

Main Products:

API,nutrition supplements,plant extract,peptide,HCG,6-Aminocaproic acid

 Visit Store

Product Description
Seller Information
Inquiry History

Description
Lambrolizumab 99% white podwer cas1374853-91-4 Details
cas 1374853-91-4
Name Lambrolizumab
Ssynonym Pembrolizumab
MF N/A
Purity 99%
Application
The drug is intended for use in treating metastatic melanoma.
Lambrolizumab 99% white podwer cas1374853-91-4 Picture

Lambrolizumab 99% white podwer cas1374853-91-4 Usage
The drug is intended for use in treating metastatic melanoma.
ECHEMI Editorial Reference

Pembrolizumab (brand name Keytruda) is a PD-1 inhibitor developed by Merck & Co., Ltd. It was first approved by the FDA in 2014 for the treatment of certain patients with metastatic melanoma. In 2015, the FDA approved Keytruda (pembrolizumab) for advanced non-small cell lung cancer. Subsequently, pembrolizumab was approved for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma, as first-line treatment for certain metastatic non-small cell lung cancer patients, Hodgkin's lymphoma (cHL), and certain locally advanced or metastatic urothelial carcinoma patients. In 2025, the FDA approved pembrolizumab as neoadjuvant therapy for PD-L1+ resectable locally advanced head and neck squamous cell carcinoma, and continued as adjuvant therapy in combination with radiotherapy.
Basic Info

Product Name:
Pembrolizumab

Other Name:
Pembrolizumab;Pembrolizumab (anti-PD-1);PEMBROLIMUMAB PD-1 1374853-91-4;Pembrolizumab 25mg/ml;PembrolizumabQ: What is Pembrolizumab Q: What is the CAS Number of Pembrolizumab Q: What is the storage condition of Pembrolizumab Q: What are the applications of Pembrolizumab;Research Grade Pembrolizumab(DHH02202);MK-3475;Research Grade Pembrolizumab

CAS No.:
1374853-91-4

Molecular Weight:
0

EC Number:
807-012-2

Color/Form:
Colorless to light yellow

Categories:
Other Chemical Drugs

Characteristics

Critical Temperature & Pressure:
Store at -80°C
Seller Information

Business Type:
Trader

Main Products:
API,nutrition supplements,plant extract,peptide,HCG,6-Aminocaproic acid

Location:
Room 707, Block A, Zhongxing Times Digital Trade Port, No. 79 Xudong Street, Hongshan District, Wuhan City

Payment Terms:
TT against copy of documents,L/C

Average lead Time:
10 days

Total Annual Revenue:
$2.5 million-$5 million

Total Employees:
51-100

Year of Establishment:
2020

Company Certificates
- Verified supplier certificate
- SGS
Dingwang Technology (Wuhan) Co., Ltd located in the predominant WuHan City where is a traffic hinge of China,specilize in producing and developing pharmaceutical & its intermediates, Peptide, Nutritional supplements,food additive, Plant extracts,and in distributing the products of our own company and affiliated enterprises.
We have set up R&D center, quality inspection center and manufacturing site in Wuhan, Jiangsu and others places.
Our company has professional staff who deal with chemical R&D and scientific management, and holds several sets of analyzing instruments with high efficiency and high sensitivity, such as HPLC, GC and Spectrophotometer. Meanwhile, we possess of complete Q.A. and Q.C. system, supply chemical products with good quality and custom-tailored products according to our clients' requirement.
We have professional sales team, focus on quality and service, and we have achieved excellent performance over the years. Our company is committed to the development of international market , our products are mainly exported to many countries and regions, such as Europe, America, South-east Asia, the Middle East and Africa etc.
With our constant efforts and good service, We sincerely hope to establish long-term cooperation and common development with our customers.

Inquiry History

3 Inquiries

Country	Product	Purchase Quantity	Date Posted
Netherlands	High quality Pembrolimumab/ supplier with competitive price in stock-Rechems Cas No: 1374853-91-4	1 KG	Jan 2, 2025
Netherlands	pembrolizumab	1 KG	Jan 2, 2025
South Korea	pembrolizumab	10 G	Nov 28, 2024

Post an enquiry for this product

More Choices Find All Products for Sale 

Product Name	Grade / Content	Price	Supplier Name	Details
Pembrolizumab (high qualified)	/	$4-5/KG FOB	Hangzhou zhongqi chem co.,Ltd	Inquiry
Best Quality 99% Dexmedetomidine hydrochloride CAS:145108-58-3 From Hyperchem	Pharmaceutical Grade/99.9	$26-30/G FOB	Hangzhou Hyper Chemicals Limited	Inquiry
pembrolimumab	Industrial Grade/99	$100/Unit EXW	Wuhan Pnq Int Trade Co., Ltd	Inquiry
Pembrolizumab1374853-91-4	/		SHANDONG LOOK CHEMICAL CO.,LTD	Inquiry
Hot Selling Pembrolizumab 1374853-91-4 Factory Supply Raw Materials High Qulity Wholesale price	USP / EP / BP / JP Grade/99.9		hubei bocare chemical Co.ltd	Inquiry

Lambrolizumab 99% white powder cas1374853-91-4 senwayer

Product Description

Seller Information

Inquiry History

More Choices Find All Products for Sale 

Related Searches

More from this Seller

cas	1374853-91-4
Name	Lambrolizumab
Ssynonym	Pembrolizumab
MF	N/A
Purity	99%
Application	The drug is intended for use in treating metastatic melanoma.